Ashram Online.com Ltd vs TORRENT PHARMACEUTICALS L

A side-by-side comparison of Ashram Online.com Ltd (TATIASKYLN) and TORRENT PHARMACEUTICALS L (TORNTPHARM) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.

The verdict

On the numbers, TORRENT PHARMACEUTICALS L leads TATIASKYLN vs TORNTPHARM on 10 of 14 metrics (1 tied). See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).

Valuation

How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.

0.00
P/E ratio
74.52
0.00
P/B ratio
19.76
0.00%
Dividend yield
0.78%
₹-0.11
EPS
₹63.92

Profitability

How efficiently each company turns capital and sales into profit. Higher is better.

-1.16%
Return on equity
27.40%
0.84%
Return on capital
15.00%
-85.42%
EBITDA margin
33.00%
-27.08%
Net margin
15.29%

Growth

Three-year compounded growth. Faster-growing businesses can justify a higher valuation.

7.17%
Revenue CAGR (3Y)
13.27%
Profit CAGR (3Y)
19.75%

Size & financial health

Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.

₹0 Cr
Market cap
₹1.61L Cr
₹0 Cr
Revenue
₹13,980 Cr
₹-0 Cr
Net profit
₹2,138 Cr
0.00
Debt / equity
1.79
Ashram Online.com Ltd
  • + ["Stock is trading at 0.59 times its book value"]
  • ["Company has low interest coverage ratio.", "The company has delivered a poor sales growth of 4.24% over past five years.", "Promoter holding is low: 25.4%", "Company has a low return on equity of -0.58% over last 3 years.", "Company has high debtors of 471 days."]
TORRENT PHARMACEUTICALS L
  • + ["Company has a good return on equity (ROE) track record: 3 Years ROE 26.2%", "Company has been maintaining a healthy dividend payout of 57.8%"]
  • ["Stock is trading at 19.8 times its book value", "The company has delivered a poor sales growth of 11.8% over past five years.", "Company might be capitalizing the interest cost"]
Ashram Online.com Ltd full analysis TORRENT PHARMACEUTICALS L full analysis

This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.